Targets › IL13RA2
6 programs from 4 companies in 14 trials: 14 Phase 1; Oncology; next expected readout Jan 2027.
Cell surface receptor that plays a role in the regulation of IL-13-mediated responses. Functions as a decoy receptor that inhibits IL-13- and IL-4-mediated signal transduction via the JAK-STAT pathway and thereby modulates immune responses and inflammation. (UniProt, Q14627)
Open in Phaseline: the race on IL13RA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expr IL13Rα2-specific CAR-T cells with 41BB co-stimulatory domain and truncated CD19 marker | IL13RA2 | Phase 1 | Ependymoma; Malignant Brain Neoplasm | Jan 2027 |
| Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| City of Hope Medical Center | IL13Ra2-specific CAR Tcm cells CAR-T cell expressing IL13 ligand binding domain targeted to IL13Ra2 | IL13RA2 | Phase 1 | Recurrent Glioblastoma | May 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy Bispecific CAR-T cell therapy targeting B7H3 and IL13Ra2 | B7H3, IL13RA2 | Phase 1 | Refractory Glioblastoma | Dec 2027 |
| City of Hope Medical Center | IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-exp IL13RA2-targeted CAR-T cell therapy with 4-1BB co-stimulation and truncated CD19 | IL13RA2 | Phase 1 | Recurrent Glioblastoma | – |
| Anusha Kalbasi | IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-exp IL13RA2-specific CAR-T cell therapy with 4-1BB co-stimulatory domain and truncated CD19 | IL13RA2 | Phase 1 | Metastatic Malignant Solid Neoplasm | – |
Recurrent Glioblastoma (3) Non-Small Cell Lung Cancer (2) Ependymoma (1) Malignant Brain Neoplasm (1) Metastatic Malignant Solid Neoplasm (1) Breast Cancer (Locally Advanced or Metastatic) (1) Glioblastoma (1) Advanced Hepatocellular Carcinoma (HCC) (1) Breast Cancer (Advanced/Metastatic) (1) Malignant Glioma (1) Refractory Glioblastoma (1)
mixed (4), other (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.